00 days
00 hrs
00 mins
00 sec

Download Program
5 October
6 October
7 October
8 October




5 October

HALLS

HEMATOLOGY PROGRAM

 

 

13.00 - 13.10

OPENING REMARKS OF EHOC 2022 - GIUSEPPE SAGLIO - BİROL GÜVENÇ - SERDAR BEDİİ OMAY

 

 

13.10 - 13.40

OPENING LECTURE - Can Immune Therapy Cure AML? - Robert Gale

Chair: Serdar Bedii Omay

 

 
 

SESSION 1: Low Grade NHLs (Turkey & Macedonia & Croatia & Serbia)

Chairs: Burhan Ferhanoglu - Rajko Kusec

 

 

13.40 - 14.00

Chemotherapy-Free Approach in the Treatment of Follicular Lymphoma

Ozan Salim

 

 

14.00 - 14.20

How I Treat MALT Lymphomas

Irina Panovska

 

 

14.20 - 14.40

How I Treat Nodal and Splenic Marginal Zone Lymphoma?

Tayfur Toptaş

 

 

14.40 - 15.00

How I Treat Waldenstrom Disease?

Nebojsa Andjelkovic

 

 

15.00 - 15.20

General Discussion Chair: Hüseyin Saffet Beköz

 

 

15.20 - 15.50

amgen

SATELLITE SYMPOSIUM
Carfilzomib in Relapsed/Refractory Multiple Myeloma
Chair:Mehmet Turgut
Speaker:Mustafa Çetiner

 

 
 

 

 

15.50 - 16.20

COFFEE BREAK

 

 

 

 
 

SESSION 2 - High-Grade NHLs (Turkey and Azerbaijan)

Chairs: Burhan Ferhanoglu - George Janossy

 

 

16.20 - 16.40

Treatment of R/R DLBCL in Transplant Ineligible Patients

Tayfur Toptaş

 

 

16.40 - 17.00

BV Versus Cheq-Point Inhibitors? Which One? When? Why Should Be Perefered?

Murat Özbalak

 

 

17.00 - 17.20

Treatment of Mantle Cell Lymphoma in Transplant Non-Eligible Patients

Valeh Huseynov

 

 

17.20 - 17.40

How I Treat Double-Hit Lymphoma and High Grade B Cell Lymphoma (NOS)?

Carmino De Souza

 

 

17.40 - 18.00

General Discussion Chair: Olga Meltem Akay

 

 
 

SESSION 3 - SOHO 2022 Updates and Highlights

CHAIRS: Hagop Kantarjian - Mehmet Ali Özcan

   

18.00 - 18.20

SOHO State of the Art & Next Questions: AML

Hagop Kantarjian

   

18.20 - 18.40

SOHO State of the Art & Next Questions: ALL

Elias Jabbour

   

18.40 - 19.00

SOHO State of the Art & Next Questions: MDS

Guillermo Garcia Manero

   

19.00 - 19.20

SOHO State of the Art & Next Questions: CLL

Susan O’Brien

   

19.20 - 19.40

General Discussion Chair: Hakan Göker

   



6 October

HALLS

HEMATOLOGY PROGRAM

 

 

07.20 - 08.10

ORAL PRESENTATION SESSIONS Ömür Gökmen Sevindik - Demet Çekdemir

07:20 - 07.30

A RARE Presentatıon Of Systemic Al Amyloıdosis; Pulmonary Al Amyloidosis

Simge Erdem

 

 

07.30 - 07.40

Treatment of a Patıent Diagnosed wıth Erdheım Chester’s Dısease in Cooperatıon with Plastıc Surgery and Hematology

Simge Erdem

 

 

07.40 - 07.50

Antıbody Responses and Safety of The Commercıally Avaılable Vaccınes Agaınst Sars-Cov-2 Vırus In Allografted Patıents: Real World Data From a Sıngle Center

Panayois Kaloyannidis

 

 

07.50 - 08.00

Coronavirus Anxıety Level and Covıd 19 Vaccıne Attitude Among Hematologıcal Malıgnancy Patıents

Zeynep Tuğba Güven

 

 
 

SESSION 4 - MPNs

CHAIRS: Tariq Mughal - Güray Saydam

 

 

08:20 - 08.40

Treatment Landscape in Myelofibrosis

Daniela Cilloni

 

 

08.40 - 09.00

Interfierans in MPN's

Selami Koçak Toprak

 

 

09.00 - 09.20

Moleculer Profiling of MPN

Tariq Mughal

 

 

09.20 - 09.40

PV New Guidelines

Tiziano Barbui

 

 

09.40 - 10.00

General Discussion Chair: Ahmet Ifran

 

 

10.00 - 10.30

COFFEE BREAK

 

 

 

 
 

SESSION 5 - ALL (ABHH)

CHAIRS: Carmino De Souza - Osman İlhan

 

 

10.30 - 10.50

Update on ALL Therapy in 2022: How Should Be Treated

Dieter Hoelzer

 

 

10.50 - 11.10

Management of Ph-positive and Ph-like ALL in 2022

Robin Foà

 

 

11.10 - 11.30

Ph+ ALL in Brazil

Welington Fernandes da Silva Jr.

 

 

11.30 - 11.50

How To Perform Precision Medicine in South America: The Example of ALL

Eduardo Rego

 

 

11.50 - 12.10



General Discussion Chair: Pervin Topcuoğlu

 

 

 

12.10 - 12.40

novartis

SATELLITE SYMPOSIUM
Polycythemia Vera Treatment with Ruxolitinib
Chair:Ayşe Tülin Tuğlular
Speaker:Sinem Civriz Bozdağ - Polycythemia Vera Treatment Journey
Speaker:Mehmet Hilmi Doğu - Ruxolitinib Experience with Cases

 

 

 

 

12.40 - 13.40

LUNCH BREAK

 

 

 

 
 

SESSION 6 - MULTIPLE MYELOMA (Greece and Italy)

CHAIRS: Evangelos Terpos - Claudio Cerchione

 

 

13.40 - 13.55

Smoldering Myeloma: To Treat or Not to Treat?

Maria Victoria Mateos - Virtual

 

 

13.55 - 14.10

What is the Optimal Frontline Therapy for High-Risk Myeloma?

Angelo Maiolino

 

 

14.10 - 14.25

How I Treat Relapsed/Refractory Multiple Myeloma: Road to the Target Therapy

Claudio Cerchione

   

14.25 - 14.40

Vaccination Against SARS-CoV-2 for Myeloma Patients: Do We Need a Booster Dose and How Frequent?

Evangelos Terpos

   

14.40 - 14.55

Prognostic Factors in Multiple Myeloma: Do We Need a New ISS?

Moshe Gatt

   

14.55 - 15.20

General Discussion Chair: Ayşe Tülin Tuğlular

   
 

SESSION 7 - CLL (Middle East Societies)

CHAIRS: Ahmad Ibrahim - Sevgi Kalayoğlu Beşışık

   

15.20 - 15.40

New Insights into CLL Pathogenesis

Carlo Croce

   

15.40 - 16.00

Firstline Treatment of CLL

Ahmad Ibrahim

   

16.00 - 16.20

Treatment of R/R CLL

Ahmad Alaskar

   

16.20 - 16.40

MRD in CLL

Tamar Tadmor

   

16.40 - 17.00

General Discussion Chair: Erdal Kurtoğlu

   

17.00 - 17.30

COFFEE BREAK

 

 

   
 

SESSION 8 - SOHO ITALY

CHAIRS: Giovanni Martinelli - Seçkin Çağırgan

   

17.30 - 17.45

SOHO Italy State of the Art & Next Questions: MM

Claudio Cerchione

   

17.45 - 18.00

SOHO Italy State of the Art & Next Questions: ALL and AML

Giovanni Martinelli

   

18.00 - 18.15

SOHO Italy Next future: ALL and AML

Daniela Cilloni

   

18.15 - 18.30

SOHO Italy State of the Art & Next Questions: CML

Giuseppe Saglio

   

18.30 - 18.45

General Discussion Chair: Şehmus Ertop

   

18.45 - 19.10

       

19.10 - 20.00

POSTER PRESENTATIONS SESION Chairs: Vahap Okan - Emin Kaya - Mehmet Ali Uçar

 

 

  An Unusual Ocular Lymphoma, Primary Intravitreal Lymphoma Diagnosed Incidentally Nur Seda İbili Çetinkaya  
  Eculizumab Dose Adjustments During Pregnancies in Paroxysmal Nocturnal Hemoglobınurıa: A Single Center Experience. Semra Aydın  
  Evaluation and Management of Thyroid Nodules At a Tertiary Care Pediatric Cancer Center in Turkey Seda Şahin   
  Follow-Up Of Chronic Myeloid Leukemia Patients Whose Tyrosine Kinase Treatment Was Stopped: Case Series Kemal Fidan  
  Glomerular Microangıopathy with Marked Systemic Thrombotic Microangıopathy Shortly After Bortezomib in a Newly Diagnosed Poems Syndrome Patient Tarık Onur Tiryaki   
  Long-Term Outcomes Of Patıents Treated wıth Caplacizumab For Immune-Mediated Thrombotic Thrombocytopenic Purpura (ITTP): The Post-Hercules Study Özgür Pektaş  
  Prevention Can be the Best Tool For Adult T-Cell Leukemia. Updated T-Cell Brazil Project Carmino De Souza  
  Quality of Life in Hematological Patients in the Post-Covid Era Weronika Lebowa   
  Rectal Cancer Distance to the Anal Verge and the T Staging: Magnetic Resonance Imaging Findings Abdalraouf Omar  
  Relapsed Mantle Cell Lymphoma with Isolated Central Nervous System Involvement That Treated with Ibrutinib; A Case Report and Lıterature Review Pınar Tığlıoğlu  
  Rituximab Induced Lung Disease in a Mantle Cell Lymphoma Patient Receıving Maintenance: Case Presentation Fehmi Hindilerden  
  Rituximab-Induced Severe Acute Thrombocytopenıa in a Patient with Splenic Marginal Zone Lymphoma Taha Ulutan Kars  
  Risk Assessment For Newly Diagnosed, Fit and Young Patients with Multiple Myeloma, in The Era of Novel Treatment Modalities: Are There Any Additional Factors to be Under Consideration? Panayotis Kaloyannidis  
  The Diversıty of Presentation and Management of Subcutaneous Panniculitis –Like T-Cell Lymphoma with Assocıated Hemophagocytic Syndrome - Case Series Analysis. Justyna Jedras  
  The Relationship Between Ferritin Level and Thrombosis in Patıents with Difuse Large B-Cell Lymphoma Buğra Sağlam  
  Treatment-Free Remıssion in Patients with Chronic Myeloid Leukemia: Management Approaches Vasile Musteata  
  Vitamin B 12 Deficiency Mimicking Thrombotic Microangıopathy: A Case Report Müzeyyen Aslaner Ak  
  Is There Any New Prognostic Score For Peripheral T-Cell Lymphoma? Derviş  Murad Akkurt  
  HBH Disease and Systemic Lupus Erythematosus Nuray Mammadova  
  The Successful Major Surgery in a Patient with Inherited FVII Defıciency and a Huge Nasopharyngeal Angıofibroma Ayşegül Ünüvar  
  Assocıation of NF-1 and Moyamoya Syndrome : Case Report Şifa Şahin   
  Serum Total Oxidant and Antıoxidant Status in Children with Cancer Yasin Yılmaz  
  Succınate Dehydrogenase Subunit B Deficient Pediatric Gist Melek Yaman Ortaköylü   
  Synovial Sarcoma Arising in the Retromolar Trigone: A Rare Presentation Asma Saleem  
  Trametinib Experıence in A Braf P.N 486 _P490del Mutation Positive Langerhans Cell Histıocytosis Sevim Gencel Karaaslan  
  Efficacy of Furosemide in Methotrexate Clearance in Patients Treated with High Dose Methotrexate Saqib Khan  

 




7 October

HALLS

HEMATOLOGY PROGRAM

 

 

07.20 - 08.10

ORAL PRESENTATION SESSIONS Chair: Şebnem İzmir Güner - Mehmet Sinan Dal

07:20 - 07.30

Humoral Immunity Responses After Vaccination for Hepatitis B Virus in Autografted Patients: a Single Center Experıence

Panayotis Kaloyannıdıs

 

 

07.30 - 07.40

Infectıous Complications in Chronic Lymphocytic Leukemia – Challenging Issues of Hemato-Oncology

Vasile Musteata

 

 

07.40 - 07.50

Intrapleural Therapy to Disrupt Il-6/Il-8 Juxtactine Sıgnalling to Block Tumor Emt -and to Drıve Systemic Anti-Tumor Immunity

Vera Donnenberg

 

 

07.50 - 08.00

Low Incidence of Central Nervous System (CNS) Relapse of Diffuse Large B-Cell Lymphoma Despite Limited Use of Intrathecal Prophylaxis

Aamer Aleem

 

 

08.00 - 08.10

The Acute Lymphoblastıc Leukemia of Down Syndrome

Mehmet Sezgin Pepeler

 
 

Session 9 - CML (ELN Network)

CHAIRS: Giuseppe Saglio - Mehmet Turgut

 

 

08.20 - 08.35

Updates in CML Treatment

Pia Raanani

 

 

08.35 - 08.50

Third Line Therapy for Resistant and Intollerante Patients

Andreas Hochhaus - Virtual

 

 

08.50 - 09.05

Molecular Monitoring in CML Patients Who Discontinue the TKI Therapy: Minimum Requirements

Naeem Chaundri

 

 

09.05 - 09.20

How to Deal with Comorbidities in CML Patients

Mohamed Yassin

 

 

09.20 - 09.35

CML Blast Crises Therapy

Tomasz Sacha

 

 

09.35 - 10.00

General Discussion Chair: Deniz Sargın

 

 

10.00 - 10.30

COFFEE BREAK

 

 

 

 
 

SESSION 10 - PERSPECTIVES OF ALLOTRANSPLANT in MYELOID NEOPLASIAS (ROHS)

CHAIRS: Elena Morzova - Ali Ünal

 

 

10.30 - 10.50

Role of AlloHSCT in Therapy of BC CML

Elena Morozova

 

 

10.50 - 11.10

Results of HSCT in Primary and Secondary MDS

Nikolay Tsvetkov

 

 

11.10 - 11.30

Bridge Therapy with Ruxolitinib Before Allo HSCT in MF Patients

Maria Barabanshikova

 

 

11.30 - 11.50

Optimal Time for Allo HSCT in AML

Anna Smirnova

 

 

11.50 - 12.10

General Discussion Chair: Mehmet Yılmaz

 

 

12.10 - 12.40

astellas

SATELLITE SYMPOSIUM
On The Way of a Longer OS and a Higher CR, Name of the Hope: XOSPATA
Chair:Sevgi Kalayoğlu Beşışık
Speaker:Ömür Gökmen Sevindik

 

 

 

 

12.40 - 13.40

LUNCH BREAK

 

 

 

 
 

SESSION 11 - BONE MARROW TRANSPLANTATION (EBMT)

CHAIRS: Anna Sureda (Virtual) - Nilgün Sayınalp

 

 

13.40 - 14.00

Reduced Intense Conditioning for Allogeneic Stem Cell Transplantation in AML

Arnon Nagler

   

14.00 - 14.20

FLT3 Mutated AML: Prevention and Treatment of Post-Transplant Relapse

Ali Bazarbahchi

   

14.20 - 14.40

Haploidentical Stem Cell Transplantation in AML; Impact of Graft Versus Host Disease Prophylaxis

Giorgia Battipaglia - Virtual

   

14.40 - 15.00

The Role of Second Allogeneic Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Myelogenous Leukemia

Fabio Ciceri

   

15.00 - 15.20

General Discussion Chair: Zafer Gülbaş

   
 

SESSION 12 - AML (SMOP)

CHAIRS: Munira Moosajee - Berksoy Şahin

   

15.20 - 15.40

The landscape of AML (Non-Transplant)

Munira Moosajee

   

15.40 - 16.00

Transplant Indications and Strategies in AML

Raheel Iftikhar

   

16.00 - 16.20

New Vulnerable Targets in AML

Giovanni Martinelli

   

16.20 - 16.40

Treatment of AML in Elderly and Fragile Patients

Alessandro Isidori

   

16.40 - 17.00

General Discussion Chair: Orhan Ayyıldız

   

17.00 - 17.30

COFFEE BREAK

 

 

   

17.30 - 18.00

abbvie

SATELLITE SYMPOSIUM
A New Hope in AML Powered by V
Topic: Venclyxto Therapy Outcomes in Newly Diagnosed AML Patients Ineligible for Intensive Chemotherapy
Chair:Seçkin Çağırgan
Speaker: Sinem Civriz Bozdağ

 

 

 

 

 

SESSION 13 - MDS (Israel Society of Hematology)

CHAIRS: Moshe Mittelman - Mustafa Çetiner

   

18.00 - 18.20

MDS 2022: Yesterday - Today and Tomorrow

Moshe Mittelman

   

18.20 - 18.40

Has There Been Real Improvements in the Treatment of MDS

Charles Schiffer

   

18.40 - 19.00

Hereditary Bone Marrow Failure Syndromes

Drorit Merkel

   

19.00 - 19.20

Lessons from the European and Israel National MDS Registry

Galia Stemer

   

19.20 - 19.40

Invasive Fungal Infections in MDS Patients

Sesin Kocagöz

   

19.40 - 20.00

General Discussion Chair: Mustafa Nuri Yenerel

   



8 October

HALLS

HEMATOLOGY PROGRAM

 

 

07.20 - 08.10

ORAL PRESENTATION SESSIONS Chairs: Güven Yılmaz-Leylagül Kaynar

07:20 - 07.30

An Updated of Pioneer Project to Collect Data of T-Cell NHL Patients Among Five Regions of Brazil. T-Cell Brazil Project

Carmino De Souza

 

 

07.30 - 07.40

Updated Progression-Free Survival (Pfs) and Depth of Response in Ikema, a Randomized Phase 3 Trial of Isatuximab, Carfilzomib and Dexamethasone (ISA-KD) Vs KD in Relapsed Multiple Myeloma (MM)

Özgür Pektaş

 

 

07.40 - 07.50

Immunophenotypic Features Of Molecular Subtypes Of Breast Cancer

Svetlana Chulkova

 

 

07.50 - 08.00

Real-Life Study of Bio-Clinical Follow-Up After Bnt162b2 Mrna Covid-19 (BNTVC) Vaccination İn 235 Patients (PTS) İncluding 225 With Hematological Malignancies (HM).

Jean Francois Rossi

 
 

SESSION 15 - PNH AND ANTITHROMBOTIC THERAPY

CHAIRS: Drew Provan - Mehmet Sönmez

 

 

08.20 - 08.35

Emerging Data for Cancer Associated Thrombosis

Piera Sivera

 

 

08.35 - 08.50

Thrombo-inflamation in MPN's

Alessandro Lucchessi

 

 

08.50 - 09.05

Vascular Diseases in PNH

Hanan Hamed

 

 

09.05 - 09.20

How Will We Manage ITP After The Pandemic?

Drew Provan

 

 

09.20 - 09.35

How We (will) Treat PNH?

Semra Aydın

 

 

09.35 - 10.00

General Discussion Chair: Fahri Şahin

 

 

10.00 - 10.30

COFFEE BREAK

 

 

 

 

10.30 - 11.00

bms
erkim

SATELLITE SYMPOSIUM
Combination treatments with Imids for Multiple Myeloma patients
Chair:Birol Güvenç
Speaker:Serdar Bedii Omay

 

 
 

 

 
 

SPECIAL LECTURE

Chairs: Albert Donnenberg - Birol Güvenç

 

 

11.00 - 11.30

The Future of Engineered T-Cell Therapeutics

Bruce Levine

 

 
 

SESSION 16 - CELLULAR THERAPY IN CANCER

Chairs: Jean Francois Rossi

 

 

11.30 - 11.50

From Allogenic Transplantation to Precision Immune Therapy

Jean Francois Rossi

 

 
 

CELLULAR THERAPY: CAR T-CELLS IN HEMATOLOGICAL MALIGNANCIES

Chairs: Nikolay Tupitsyn

 

 

11.50 - 12.10

European Experience from Barcelona – In-House Preparation and Clinical Results

Manel Juan

 

 

12.10 - 12.30

Chinese Experience Tumor Burden and CAR-T Cell-Derived IL-6: Predictive Value in R/R B-ALL

Wu Depei Suzhou

 

 

12.30- 12.50

USA Experience: IN-HOUSE Preparation: Prospects and Problems

Albert Donnenberg

   
 

OTHER MODALITIES OF CELLULAR THERAPY

Chairs: Vera Donnenberg

   

12.50- 13.10

Intrapleural Therapy To Drive Systemic Anti-Tumor Immunity

Vera Donnenberg

   

13.10- 13.30

Generating Not Genetically-Modified, Car-Like, NK Cells

Martin Villalba

   

13.30 - 13.50

Round Table: Present and Future of Cellular Therapy From Bench to Bedside

Chairs: Jean Francois Rossi - Oral Nevruz

   

13.50 - 14.10

CLOSING REMARKS OF EHOC 2022